Teleflex Incorporated (NYSE:TFX) CEO Benson Smith sold 2,000 shares of Teleflex stock in a transaction on Monday, December 4th. The stock was sold at an average price of $258.10, for a total transaction of $516,200.00. Following the sale, the chief executive officer now directly owns 76,634 shares in the company, valued at approximately $19,779,235.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Teleflex Incorporated (TFX) traded down $1.23 during midday trading on Wednesday, hitting $251.75. The stock had a trading volume of 341,500 shares, compared to its average volume of 260,808. Teleflex Incorporated has a fifty-two week low of $151.22 and a fifty-two week high of $271.23. The company has a debt-to-equity ratio of 0.88, a quick ratio of 3.70 and a current ratio of 4.72. The stock has a market cap of $11,396.56, a price-to-earnings ratio of 31.27, a PEG ratio of 2.16 and a beta of 1.09.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 EPS for the quarter, topping the consensus estimate of $2.01 by $0.11. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The business had revenue of $534.70 million for the quarter, compared to analyst estimates of $522.94 million. During the same quarter in the previous year, the firm earned $1.80 EPS. The company’s quarterly revenue was up 17.3% compared to the same quarter last year. equities research analysts expect that Teleflex Incorporated will post 8.35 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 15th. Stockholders of record on Wednesday, November 15th will be issued a dividend of $0.34 per share. The ex-dividend date is Tuesday, November 14th. This represents a $1.36 annualized dividend and a dividend yield of 0.54%. Teleflex’s dividend payout ratio is presently 24.82%.

Several brokerages have issued reports on TFX. Needham & Company LLC lifted their target price on shares of Teleflex from $228.00 to $237.00 and gave the stock a “buy” rating in a research note on Tuesday, September 5th. Piper Jaffray Companies began coverage on shares of Teleflex in a research note on Friday, November 10th. They set an “overweight” rating and a $295.00 target price on the stock. Morgan Stanley raised shares of Teleflex from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $220.00 to $274.00 in a research note on Wednesday, September 6th. KeyCorp reaffirmed a “hold” rating on shares of Teleflex in a research note on Wednesday, September 6th. Finally, Jefferies Group reaffirmed a “buy” rating and set a $253.00 target price (up previously from $230.00) on shares of Teleflex in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have given a buy rating to the company’s stock. Teleflex has an average rating of “Hold” and a consensus target price of $274.44.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Toronto Dominion Bank raised its holdings in shares of Teleflex by 14.5% during the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock worth $115,000 after acquiring an additional 70 shares during the period. Advisory Services Network LLC raised its holdings in shares of Teleflex by 933.8% during the 2nd quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock worth $172,000 after acquiring an additional 747 shares during the period. Cornerstone Capital Management Holdings LLC. purchased a new position in shares of Teleflex during the 2nd quarter worth $175,000. Coldstream Capital Management Inc. purchased a new stake in Teleflex in the 3rd quarter valued at about $226,000. Finally, Calamos Advisors LLC purchased a new stake in Teleflex in the 2nd quarter valued at about $206,000. Institutional investors and hedge funds own 89.31% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at

About Teleflex

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.